循环肿瘤DNA变化用于抗PD1免疫治疗早期监测:一项概念验证研究
这项前瞻性先导研究在Institut Curie纳入接受纳武利尤单抗或帕博利珠单抗单药治疗的非小细胞肺癌、葡萄膜黑色素瘤或微卫星不稳定结直肠癌患者,于基线及第8周检测循环肿瘤DNA水平。15例中10例基线可检出ctDNA,第8周ctDNA水平同步变化与肿瘤大小显著相关(r=0.86;P=0.002),第8周ctDNA可检出是PFS(HR=10.2;95%CI 2.5-41,P<0.001)和OS(HR=15;95%CI 2.5-94.9,P=0.004)的显著预后因素。
要点
- 15例中10例基线可检出ctDNA,第8周ctDNA变化与肿瘤大小同步变化显著相关(r=0.86;P=0.002)。
- 第8周ctDNA转为不可检出者获得明显且持久的治疗反应。
- 第8周ctDNA可检出与更差PFS(HR=10.2;95%CI 2.5-41,P<0.001)和OS(HR=15;95%CI 2.5-94.9,P=0.004)相关。
核心结论
- 该概念验证研究首次证明定量ctDNA监测是评估抗PD-1药物治疗患者肿瘤反应的有价值工具。
研究设计与样本
- 前瞻性先导研究,在Institut Curie纳入接受纳武利尤单抗或帕博利珠单抗单药治疗的非小细胞肺癌、葡萄膜黑色素瘤或微卫星不稳定结直肠癌患者,共15例。
- 于基线及第8周依据突变类型采用双向焦磷酸解激活聚合、微滴数字PCR或二代测序检测ctDNA水平,疗效影像学评估采用免疫相关反应标准。
主要发现
- 15例中10例基线可检出ctDNA。
- 第8周ctDNA水平同步变化与肿瘤大小显著相关(r=0.86;P=0.002)。
- 第8周ctDNA转为不可检出者获得明显且持久的治疗反应。
- 第8周ctDNA可检出是无进展生存的显著预后因素(HR=10.2;95%CI 2.5-41,P<0.001)。
- 第8周ctDNA可检出是总生存的显著预后因素(HR=15;95%CI 2.5-94.9,P=0.004)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recent clinical results support the use of new immune checkpoint blockers (ICB), such as anti-PD-1 (e.g. nivolumab and pembrolizumab) and anti-PD-L1 antibodies. Radiological evaluation of ICB efficacy during therapy is challenging due to tumor immune infiltration. Changes of circulating tumor DNA (ctDNA) levels during therapy could be a promising tool for very accurate monitoring of treatment efficacy, but data are lacking with ICB. PATIENTS AND METHODS: This prospective pilot study was conducted in patients with nonsmall cell lung cancer, uveal melanoma, or microsatellite-instable colorectal cancer treated by nivolumab or pembrolizumab monotherapy at Institut Curie. ctDNA levels were assessed at baseline and after 8 weeks (w8) by bidirectional pyrophosphorolysis-activated polymerization, droplet digital PCR or next-generation sequencing depending on the mutation type. Radiological evaluation of efficacy of treatment was carried out by using immune-related response criteria. RESULTS: ctDNA was detected at baseline in 10 out of 15 patients. At w8, a significant correlation (r = 0.86; P = 0.002) was observed between synchronous changes in ctDNA levels and tumor size. Patients in whom ctDNA levels became undetectable at w8 presented a marked and lasting response to therapy. ctDNA detection at w8 was also a significant prognostic factor in terms of progression-free survival (hazard ratio = 10.2; 95% confidence interval 2.5-41, P < 0.001) and overall survival (hazard ratio = 15; 95% confidence interval 2.5-94.9, P = 0.004). CONCLUSION: This proof-of-principle study is the first to demonstrate that quantitative ctDNA monitoring is a valuable tool to assess tumor response in patients treated with anti-PD-1 drugs.
引用
- Cabel L, Riva F, Servois V, et al. Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study. Ann Oncol. 2017. PMID: 28459943. doi:10.1093/annonc/mdx212
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。